Featured

What Merck's treatment means for the company, vaccine makers



Published
Geoff Meacham, senior pharma analyst, BofA Securities, on what Merck's new Covid treatment could mean for the company and the industry, as a whole. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Karen Finerman, Steve Grasso and Nadine Terman.
Category
Health
Be the first to comment